Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Cumberland Pharmaceuticals (CPIX) over the last 15 years, with Sep 2025 value amounting to $23,788.

  • Cumberland Pharmaceuticals' Capital Expenditures rose 54.68% to $23,788 in Q3 2025 from the same period last year, while for Sep 2025 it was $100,187, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $66,461 for FY2024, which is 76.37% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Capital Expenditures stood at $23,788 for Q3 2025, which was down 10.19% from $26,486 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Capital Expenditures registered a high of $137,255 during Q2 2022, and its lowest value of -$153,528 during Q4 2022.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Capital Expenditures value was $41,621 (recorded in 2024), while the average stood at $40,512.
  • Within the past 5 years, the most significant YoY rise in Cumberland Pharmaceuticals' Capital Expenditures was 810.60% (2022), while the steepest drop was 1,797.00% (2022).
  • Cumberland Pharmaceuticals' Capital Expenditures (Quarterly) stood at $9,047 in 2021, then tumbled by 1,797.00% to -$153,528 in 2022, then spiked by 131.70% to $48,673 in 2023, then crashed by 95.31% to $2,283 in 2024, then skyrocketed by 54.68% to $23,788 in 2025.
  • Its last three reported values are $23,788 in Q3 2025, $26,486 for Q2 2025, and $47,630 during Q1 2025.